Products

splatoon-salmonrun.com

スプラトゥーン3サーモンラン攻略Wikiやサーモンランスケジュールを掲載!アップデートやギア・ブキ、ビッグランやバイトチームコンテストの最新情報をお届けします。

splatoon-salmonrun.com Productivity & Collaboration / Notes & Knowledge Management

AI Benchmark
Desktop
Mobile
Monthly visits
325.4K
Down52.8%MoMSep 2026
Public revenue
Undisclosed
No public revenue evidence yet
Entry price
Unknown
No monthly subscription pricing
Launched
3y ago
2023-05-17 · Est.

Traffic

Monthly visitsData through Sep 2026 · Oct 2026 pending
Events2 changes

Marketing moves

Launches, search & content, referrals, promotions
  • New product launchLaunch

    May 17, 2023 · 3y agoWebsite

Traffic sources

Sep 2026

Traffic breakdown

Channels

  • Organic Search45%
  • Direct27%
  • Referrals17%
  • Social9%
  • Other1%

Countries

  • Japan97%
  • Taiwan2%
  • United States1%

Search

Domain authority —Domain registered 2023-05-17

KeywordMonthly volume
サーモンラン スケジュール2,550
サーモンラン2,510
ウズシオクリスタル稼ぎ2,270
レイダース 攻略1,920
スプラトゥーン レイダース 最強武器750

Traffic data: Vaneform

Pricing

Pricing page not identified yet, or no public pricing listed.

Pages & changes

Tracked since 2026-11-04

Key pages

Weekly snapshots

Changes

  1. Nov 1 · 13d ago

    Adopted technology: Google Tag ManagerFeatures

    —→Google Tag Manager

  2. Nov 1 · 13d ago

    Adopted technology: Priority HintsFeatures

    —→Priority Hints

Questions & evidence

How much website traffic does splatoon-salmonrun.com get?
Vaneform estimates 325.4K website visits in 2026-09. Visits can include repeat visits; this estimate measures web traffic separately from paying customers or revenue.Source
What is splatoon-salmonrun.com and what platforms does it support?
splatoon-salmonrun.com is catalogued under Notes & Knowledge Management: スプラトゥーン3サーモンラン攻略Wikiやサーモンランスケジュールを掲載!アップデートやギア・ブキ、ビッグランやバイトチームコンテストの最新情報をお届けします。. Supported platforms: Web.

Related products in this category

Productivity & Collaboration / Notes & Knowledge Management

These products share a catalog category. Compare customer tasks, features and deployment requirements before treating them as alternatives.